Biogen (BIIB) investor relations material

Strategic transformation and capital allocation

• Shifted from a neuroscience-focused, high-risk model to a diversified portfolio including immunology, nephrology, rheumatology, dermatology, and rare diseases.

• Business development and acquisitions, such as Apellis and Hi Bio, have expanded the pipeline and commercial reach.

• Ten phase III trials are set to read out soon, potentially leading to eight product launches across five molecules.

• Early-stage development and capital-efficient acquisitions are prioritized for future growth.

• Increased competition in early-stage immunology assets, with expanded supply due to global entrants like China.

Alzheimer's disease and LEQEMBI updates

• Uptake of LEQEMBI has been slower than expected due to care pathway complexity and reimbursement challenges.

• Adoption of blood-based diagnostics has improved patient triage and eligibility, increasing yield from 50% to 70%.

• Subcutaneous formulation for induction and maintenance is now approved, with broader uptake expected after Part D reimbursement in January.

• Over 80% of medical formulary exemptions are approved, supporting access.

• Early treatment studies (AHEAD 3-45) may redefine the market, with readout expected in 2028.

Competitive landscape and pipeline in Alzheimer's

• Current market dominated by two main molecules, with new entrants like Roche's trontinemab not expected soon.

• Early intervention may yield better outcomes, as shown by stability or improvement in low tau patients.

• Next-generation amyloid and tau-targeting therapies are in development, aiming to address growing unmet need.

• Positive results from competitors' studies may not directly translate due to differences in endpoints and populations.